Shutdown dims lights at FDA, NIH and CDC

Share this article:
Shutdown dims lights at FDA, NIH and CDC
Shutdown dims lights at FDA, NIH and CDC

The government shutdown that went into effect at midnight put 800,000 government employees out of work for the duration. The fallout includes 40,513 Health and Human Services employees, or 52% of the department's staff, while 48% will continue to come in and be paid.

At the FDA, this means 45% of the agency's staff has been sent home. Assistant commissioner of media affairs Steven Immergut emailed MM&M that of the 55% of staff who are allowed to work, 74% of them are funded by user fees. The shutdown means the FDA will not be able to perform tasks including routine inspections, some compliance activities, and “the majority of the laboratory research necessary to inform public health decision-making.”

Of the media affairs staff, Immergut was the only one of three media affairs specialists allowed to show. Colleagues Heidi Rebello and Erica Jefferson's out-of-office messages noted, “I am out of the office on furlough and cannot respond to your email.”

The Street's Adam Feuerstein noted last week that the shutdown could mean Amarin (vascepta), Johnson & Johnson (simeprevir) and Gilead (sofosbuvir) see their advisory review committee days evaporate.

Also as part of the shutdown, the National Institutes of Health will not review grant applications or begin new treatment protocols, and will cease other functions. The Centers for Disease Control and Prevention is also scaling back, and will not be able to provide state and local support for infectious disease surveillance or the annual seasonal influenza programs, in addition to stopping other activities.

Although the FDA's homepage did not note the shutdown, making it appear like a normal day, the NIH's website features a big red box noting, “due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,” and forwarding users to This second site's featured news included a note that the government had shut down and provided an 800 number to call for questions, which was followed by a second story on auto-rotate encouraging readers to sign up for health exchanges. These exchanges, part of healthcare legislation that put the government in deep freeze, began accepting members today. Money had already been allocated to the exchanges, insulating them from the standoff.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...